## **Core Concept**
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Patients with DMD are at risk of developing rhabdomyolysis and malignant hyperthermia with certain anesthetics.

## **Why the Correct Answer is Right**
The correct answer, , is a non-depolarizing muscle relaxant that does not trigger malignant hyperthermia or significant rhabdomyolysis, making it safer for patients with DMD. Unlike depolarizing agents (like succinylcholine) and some volatile anesthetics, does not pose a high risk of inducing life-threatening complications in these patients.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This option might seem viable but is incorrect because it could potentially trigger malignant hyperthermia or rhabdomyolysis in DMD patients, although it's less likely with newer agents.
* **Option B:** - This option is incorrect because succinylcholine, a depolarizing muscle relaxant, can cause severe hyperkalemia in patients with DMD due to the upregulation of nicotinic acetylcholine receptors.
* **Option D:** - This option might seem appropriate but is incorrect because, although it might be used in certain contexts, it does not represent the best choice for a DMD patient undergoing surgery.

## **Clinical Pearl / High-Yield Fact**
For patients with Duchenne muscular dystrophy undergoing surgery, it is crucial to avoid agents that can precipitate rhabdomyolysis or malignant hyperthermia. The use of **total intravenous anesthesia (TIVA)** with careful selection of anesthetic agents, such as **propofol** and **opiates**, along with a non-depolarizing neuromuscular blocker like , can provide a safe anesthetic.

## **Correct Answer: .**